fbpx

UCB - PA0010 Clinical Research Study

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).

UCB - PA0010 Clinical Research Study

Minimum Age

18

Eighteen Years and Older

Diagnosis

PsA

Adult onset Psoriatic Arthritis

PLACEBO CONTROLLED

YES

Potential Placebo for 16-Weeks

DURATION

73

Total Duration is 73 Weeks

STIPEND

$55

$55 Per Visit, $1,925 Max

Patient Benefits

Patients who screen and then enroll in the study will receive:

  • Doctor Assessements
  • Lab work and Safety Follow-ups
  • Study drug (active, comparator or placebo)
  • $55.00 per completed study visit ($1,925 Maximum for the course of the study.)

Study Duration

Study Duration for Patients

The total study duration is approximately 73-weeks which consists of approximately 29 visits during the course of the study.

The study consists of three periods:

  1. Screening Period (2 to 5 weeks before the treatment starts) to see if you are eligible to participate in the study.
  2. Study Treatment Period (52 weeks). This Study Treatment period includes Double-Blind Study Treatment Period (16 weeks) and Active Study Treatment-Blind Period (36 weeks).
  3. Safety Follow-Up Visit (SFU visit) (20 weeks, after the last dose of study drug) and is applicable only for the subjects who do not enter the open-label extension study or if you leave the study.

The study may also have some unplanned visits, most commonly for repeat lab work.

Study Drug

Bimekizumab

Bimekizumab is an investigational biologic medication.

Study Location

600 Aviator Ct.
Vandalia, OH 45377

Sister Study PA0011

Inclusion Criteria

The following must be met in order to qualify for the study.

  • Male or female at least 18 years of age
  • Female subject must be postmenopausal, permanently sterilized or willing to use a highly effective method of contraception
  • Documented diagnosis of adult-onset Psoriatic Arthritis (PsA)
  • Subject must have at least 1 active psoriatic lesion(s) and/or a documented history of psoriasis (PSO)
  • Subject must be a suitable candidate for treatment with adalimumab (Humira) and has no contraindications to receive adalimumab as per the local label as assessed by the Investigator
  • Subjects currently taking NSAIDs, cyclooxygenase 2 (COX-2) inhibitors, analgesics (including mild opioids), corticosteroids, DMARDs can be allowed if they fulfill specific requirements prior to study entry

Exclusion Criteria

Patients with any of the following are ineligible to enroll in the study.

  • Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study
  • Subjects with current or prior exposure to any biologics for the treatment of Psoriatic Arthritis (PsA) or Psoriasis (PSO)
  • Subject has an active infection or a history of recent serious infections
  • Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
  • Subject has a diagnosis of inflammatory conditions other than PSO or PsA. Subjects with a diagnosis of Crohn’s disease, ulcerative colitis, or other inflammatory bowel disease (IBD) are allowed as long as they have no active symptomatic disease at Screening or Baseline
  • Subject had acute anterior uveitis within 6 weeks of Baseline
  • Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer
  • Subject has a form of PSO other than chronic plaque-type (eg, pustular, erythrodermic and guttate PSO, or drug-induced PSO)
  • Presence of active suicidal ideation, or moderately severe major depression or severe major depression
  • Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening

** Other eligibility criteria exist to enroll in the study.   Study eligibility requirements are subject to change.  STAT Research and Dr. Wolfe reserve the right to exclude patients who do qualify for other reasons. Enrollment is limited and may be closed at anytime without prior notice.

How to contact us...

1-833-STAT-833

See if you Qualify!

Complete the form below and a research coordinator will contact you regarding phone or in-person pre-screening.

A telephone number where we can contact you.

Study Investigator

Dr. Sanford Wolfe, D.O.
Dr. Sanford Wolfe, D.O.

Principal Investigator

Dr. Wolfe is a graduate of Des Moines University College of Osteopathic Medicine and has been practicing Rheumatology for over 40 years. Dr. Wolfe is board certified in Internal Medicine and Rheumatology. Dr. Wolfe is a renowned leader in regards to clinical research trials, with over 20 years of experience and led more than 120 studies within the Rheumatology therapeutic area.

[popup_anything id="3415"]
Providing a phone number allows us to notify you via text message or calls about upcoming studies.
NO SPAM! We respect your privacy and will only use this to respond to your inquiry and notify you of new studies.
Feel free to tell us more about the conditions which you have an interest in. If you've identified an enrolling study that you'd like to know more about, please let us know that here.
close-link

RAPID COVID-19 Testing
$49 - 1 Hour Results

TESTING INFO HERE
close-link
COVID-19 Testing Info